OPKO Health, Inc.
NASDAQ:OPKBiotechnology
+$0.01 today
- Market cap
- $1.25B
- Beta
- 1.49
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.28
Volume 3.06M
Average 2.59M
OPK EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
OPKO Health, Inc.NASDAQ: OPK
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.07, compared with -$0.1 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.28.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$0.21 (+29.0%) for the fiscal year ending Dec 2026, a step up from the -291.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.07-77.2% QoQ
- Last fiscal yearDec 2025
- -$0.3-291.1% YoY
- LTMMar 2026
- -$0.28-326.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.7% | +61.7% | +34.0 pp |
| 1 year | -291.1% | +29.0% | +320.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (0.30) USD
- Year-over-year change
- -291.1%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.30) | -291.1% |
| FY2024 | 2024-12-31 | (0.08) | +69.3% |
| FY2023 | 2023-12-31 | (0.25) | +45.7% |
| FY2022 | 2022-12-31 | (0.46) | -911.0% |
| FY2021 | 2021-12-31 | (0.05) | — |
EPS (Diluted) vs competitors
How OPK compares with its peers on the latest reported figures
- OPK's LTM Mar 2026 EPS (Diluted) of -$0.28 is the 2nd highest of the 11 companies compared; the peer median is -$0.96.
- Its year-over-year change of -326.3% is the lowest of 11, against a peer median of +6.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | $0.62 | +190.6% | — |
| LTM Mar 2026 | -$0.28 | -326.3% | — | |
| LTM Jun 2026 | -$0.4 | +51.0% | — | |
| LTM Mar 2026 | -$0.44 | -126.5% | — | |
| FY2025 | -$0.67 | +42.2% | — | |
| LTM Mar 2026 | -$0.9 | -7.1% | — | |
| LTM Mar 2026 | -$1.02 | +20.9% | — | |
| LTM Jun 2026 | -$1.36 | +28.8% | — | |
| LTM Mar 2026 | -$2.38 | -78.9% | — | |
| LTM Sep 2026 | -$3.68 | -14.6% | — | |
| LTM Mar 2026 | -$4.3 | -284.0% | — | |
| Peer median (excluding OPK) | -$0.96 | +6.9% | — | |
Competitors are the stored peer set for OPK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77B | 1B | 863.5M | 713.14M | 606.88M |
| Cost of Revenue | 1.19B | 715.98M | 545.37M | 402.11M | 478.83M |
| Gross Profit | 581.52M | 288.22M | 318.13M | 311.03M | 128.05M |
| Gross Margin | 32.8% | 28.7% | 36.8% | 43.6% | 21.1% |
| Research & Development | 76.85M | 73.89M | 89.59M | 105.21M | 124.03M |
| Selling, General & Admin | 468.86M | 372.67M | 300.56M | 304.22M | 223M |
| Operating Expenses | 562.77M | 514.47M | 475.15M | 463.1M | 347.04M |
| Depreciation & Amortization | 78.72M | 108.66M | 105.3M | 98.18M | 91.63M |
| EBITDA | 83.57M | (270.81M) | (65.52M) | 135.28M | (41.3M) |
| EBITDA Margin | 4.7% | -27.0% | -7.6% | 19.0% | -6.8% |
| Operating Income | 18.75M | (226.25M) | (157.02M) | (152.07M) | (218.99M) |
| Operating Margin | 1.1% | -22.5% | -18.2% | -21.3% | -36.1% |
| Interest Income | 28K | 1.98M | 3.98M | 8.43M | 14.81M |
| Interest Expense | 18.88M | 12.06M | 13.51M | 47.47M | 108.46M |
| Other Income / Expenses | (33.4M) | (165.65M) | (27.41M) | 141.7M | (22.41M) |
| Income Before Tax | (14.65M) | (391.9M) | (184.43M) | (10.36M) | (241.39M) |
| Pre-Tax Margin | -0.8% | -39.0% | -21.4% | -1.5% | -39.8% |
| Income Tax Expense | 15.49M | (63.5M) | 4.44M | 42.84M | (15.71M) |
| Net Income | (30.14M) | (328.41M) | (188.86M) | (53.22M) | (225.68M) |
| Net Margin | -1.7% | -32.7% | -21.9% | -7.5% | -37.2% |
| EPS (Basic) | (0.05) | (0.46) | (0.25) | (0.08) | (0.30) |
| EPS (Diluted) | (0.05) | (0.46) | (0.25) | (0.08) | (0.30) |
| Weighted Avg Shares | 648.08M | 719.06M | 751.77M | 694.02M | 751.13M |
| Weighted Avg Shares (Diluted) | 648.08M | 719.06M | 751.77M | 694.02M | 751.13M |
OPKO Health, Inc.
NASDAQ:OPK
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.